Edition:
India

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

76.50EUR
22 Jun 2018
Change (% chg)

€-1.10 (-1.42%)
Prev Close
€77.60
Open
€77.60
Day's High
€78.00
Day's Low
€76.10
Volume
33,136
Avg. Vol
38,882
52-wk High
€88.60
52-wk Low
€16.75

Latest Key Developments (Source: Significant Developments)

Argenx SE Says Euronext Has Selected Argenx SE For Inclusion In BEL 20 Index On Euronext Brussels
Wednesday, 6 Jun 2018 

June 5 (Reuters) - argenx SE ::ARGENX SE SAYS EURONEXT HAS SELECTED ARGENX SE FOR INCLUSION IN BEL 20 INDEX ON EURONEXT BRUSSELS, EFFECTIVE JUNE 18, 2018.  Full Article

Argenx SE Files For Potential Mixed Shelf Offering
Saturday, 2 Jun 2018 

June 1 (Reuters) - argenx SE ::ARGENX SE FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)
Tuesday, 24 Apr 2018 

April 24 (Reuters) - ARGENX NV ::REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING.EIGHT-WEEK FOLLOW-UP DATA SHOW SEPARATION OF CLINICAL EFFICACY SCORES BETWEEN TREATMENT GROUP AND PLACEBO GROUP THROUGH DURATION OF STUDY.TOTAL AND PATHOGENIC IGG REDUCTION CORRELATES WITH DISEASE SCORE IMPROVEMENTS.  Full Article

Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma
Thursday, 12 Apr 2018 

April 12 (Reuters) - ARGENX ::TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX .AS PART OF AGREEMENT, ARGENX HAS GRANTED LEO PHARMA AN EXCLUSIVE OPTION TO OBTAIN A WORLDWIDE, EXCLUSIVE LICENSE TO ARGX-112 PROGRAM,.ARGX-112 PROGRAM AIMS TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS FOR INFLAMMATORY SKIN DISORDERS.MAY RECEIVE FURTHER REGULATORY AND CLINICAL MILESTONE PAYMENTS UP TO APPROX. EUR 100MM AS WELL AS ROYALTIES ON NET SALES OF ANY PRODUCT.  Full Article

Argenx Announces Closing Of U.S. Public Offering For Gross Proceeds Of About $266 Mln
Tuesday, 19 Dec 2017 

Dec 18 (Reuters) - Argenx Nv ::REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $266 MILLION.‍EACH OF ADSS OFFERED REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE​.‍CLOSING OF ITS PUBLIC OFFERING IN UNITED STATES OF 5,106,000 AMERICAN DEPOSITARY SHARES AT PRICE OF $52.00 PER ADS​.  Full Article

Argenx Raises About $231 Mln In Gross Proceeds In Upsized U.S. Offering
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Argenx Nv ::ARGENX RAISES APPROXIMATELY $231 MILLION IN GROSS PROCEEDS IN AN UPSIZED U.S. PUBLIC OFFERING.‍ARGENX HAS GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 666,000 ADSS​.‍PRICING OF ITS PUBLIC OFFERING IN UNITED STATES WITH ANTICIPATED GROSS PROCEEDS ABOUT $231 MILLION FROM SALE OF 4,440,000 ADSS, AT $52/ADS​.  Full Article

Argenx Announces Updated Size Of Proposed Public Offering In The U.S. To 3.5 Million ADSS
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Argenx Nv ::HAS UPDATED NUMBER OF AMERICAN DEPOSITARY SHARES ("ADSS") IN ITS UNDERWRITTEN U.S. PUBLIC OFFERING (OFFERING) TO 3.5 MILLION ADSS.NOMINAL VALUE OF EUR 0.10 PER SHARE.ALL OF ADSS IN PROPOSED OFFERING ARE TO BE SOLD BY ARGENX..  Full Article

Argenx Files For Offering Of Up To $150 Mln American Depositary Shares
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Argenx Nv ::ARGENX FILES FOR OFFERING OF UPTO $150.0 MILLION OF AMERICAN DEPOSITARY SHARES - SEC FILING.  Full Article

Argenx announces launch of proposed public offering in United States
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Argenx Nv ::ARGENX ANNOUNCES LAUNCH OF PROPOSED PUBLIC OFFERING IN THE UNITED STATES.ARGENX NV - COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $150 MILLION OF AMERICAN DEPOSITARY SHARES.ARGENX NV - EACH OF ADSS OFFERED IN OFFERING REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE.  Full Article

Argenx To Provide Updates On Phase 1/2 Clinical Trials Of ARGX-110
Monday, 11 Dec 2017 

Dec 11 (Reuters) - ARGENX NV ::TO PROVIDE UPDATES ON PHASE 1/2 CLINICAL TRIALS OF ARGX-110 IN ACUTE MYELOID LEUKEMIA AND CUTANEOUS T-CELL LYMPHOMA DURING AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.  Full Article

BRIEF-Argenx Q1 Operating Income Down At 6.9 Million Euros

* ARGENX REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE